An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic Business Decision

Conditions

Hepatocellular Carcinoma (HCC)
Cholangiocarcinoma
Esophageal Cancer
Nasopharyngeal Cancer
Ovarian Cancer
Solid Tumors

Interventions

DRUG: INCB062079

Sponsor

Incyte Corporation